Tests IgPro20 to prevent infections in people with multiple myeloma
Tests IgPro20 to prevent infection in adults with myeloma and low antibodies.
Plain-language title generated from the registry record
Registry title: Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia
Key facts
- Where
- Atlanta, Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Uniondale, United StatesSee the 9 sites
- Phase
- Phase 2
Where in United States
- Emory University (Data Collection Only)Atlanta, United StatesTaking people
- Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Suffolk-Commack (All protocol activity)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- Mount Sinai HospitalNew York, United StatesNot yet recruiting
- Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT06976476
- Record updated
- 5 October 2026
- Original description
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).Read full original descriptionShow less
Prospective Randomized Phase II Study Evaluating Efficacy and Safety of IgPro20 as Infection Prophylaxis in Patients With Multiple Myeloma and Hypogammaglobulinemia Receiving Therapy With a Bispecific Monoclonal Antibody (BsAbs)
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
Inclusion: Diagnosis of RRMM receiving a commercially available bispecific antibody; Received at least 1 but no more than 4 cycles of BsAb; Males or females greater than or equal to 18 years old at the time of consent; ECOG ≤ 3; Life expectancy > 12 months.
Exclusion: HSCT within 3 months before enrollment; Planned CAR-T therapy in the next 6 months; On current or previous IVIG (in the last 3 months); >1 major (deep-seated) infection within the preceding 3 months; HIV infection, Active HCV, or Active HBV infection; History of cancer other than MM in the last 3 years requiring active chemotherapy or radiation; Known reaction/allergy to IgG products; Intracranial hemorrhage or embolic CVA in the last 6 months; Known history of Hyperprolinemia; Neutrophils < 500 x 10\^3 per mL, Platelets < 30 x 10\^9 per mL; Creatinine Cl <30 ml/min; Pregnancy; Hyperproteinemia; Protein-losing enteropathy; Documented progression on BsAb.